174 related articles for article (PubMed ID: 24885195)
1. Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts.
Andersson G; Wennersten C; Gaber A; Boman K; Nodin B; Uhlén M; Segersten U; Malmström PU; Jirström K
BMC Urol; 2014 May; 14():36. PubMed ID: 24885195
[TBL] [Abstract][Full Text] [Related]
2. Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker.
Wennersten C; Andersson G; Boman K; Nodin B; Gaber A; Jirström K
Diagn Pathol; 2014 Oct; 9():189. PubMed ID: 25278252
[TBL] [Abstract][Full Text] [Related]
3. Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.
Boman K; Larsson AH; Segersten U; Kuteeva E; Johannesson H; Nodin B; Eberhard J; Uhlén M; Malmström PU; Jirström K
Br J Cancer; 2013 Jun; 108(11):2321-8. PubMed ID: 23652315
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.
Boman K; Segersten U; Ahlgren G; Eberhard J; Uhlén M; Jirström K; Malmström PU
BMC Urol; 2013 Apr; 13():17. PubMed ID: 23565664
[TBL] [Abstract][Full Text] [Related]
5. Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer.
Otto W; Rubenwolf PC; Burger M; Fritsche HM; Rößler W; May M; Hartmann A; Hofstädter F; Wieland WF; Denzinger S
BMC Cancer; 2012 Oct; 12():459. PubMed ID: 23043286
[TBL] [Abstract][Full Text] [Related]
6. Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.
Boman K; Andersson G; Wennersten C; Nodin B; Ahlgren G; Jirström K
Biomark Res; 2017; 5():10. PubMed ID: 28293425
[TBL] [Abstract][Full Text] [Related]
7. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
8. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
9. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
Poyet C; Buser L; Roudnicky F; Detmar M; Hermanns T; Mannhard D; Höhn A; Rüschoff J; Zhong Q; Sulser T; Moch H; Wild PJ
J Clin Pathol; 2015 Oct; 68(10):819-24. PubMed ID: 26251520
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive disease.
Storr SJ; Hoskin V; Aiyappa-Maudsley R; Ghaffari A; Varma S; Green A; Rakha E; Ellis IO; Greer PA; Martin SG
Cancer Med; 2023 May; 12(9):10908-10916. PubMed ID: 36938826
[TBL] [Abstract][Full Text] [Related]
11. Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer.
Malmström PU; Hemdan T; Segersten U
Urol Oncol; 2017 Aug; 35(8):532.e1-532.e6. PubMed ID: 28389159
[TBL] [Abstract][Full Text] [Related]
12. Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer.
Larsson A; Fridberg M; Gaber A; Nodin B; Levéen P; Jönsson G; Uhlén M; Birgisson H; Jirström K
BMC Cancer; 2012 Jul; 12():282. PubMed ID: 22769594
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma.
Heby M; Elebro J; Nodin B; Jirström K; Eberhard J
BMC Clin Pathol; 2015; 15():10. PubMed ID: 26028992
[TBL] [Abstract][Full Text] [Related]
14. High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder.
Lee YE; Chan TC; Tian YF; Liang PI; Shiue YL; Chen YS; He HL
Urol Oncol; 2019 May; 37(5):299.e7-299.e18. PubMed ID: 30660494
[TBL] [Abstract][Full Text] [Related]
15. Slingshot homolog-1 expression is a poor prognostic factor of pT1 bladder urothelial carcinoma after transurethral resection.
Luo Q; Liu Y; Zhao H; Guo P; Wang Q; Li W; Li G; Wu B
World J Urol; 2020 Nov; 38(11):2849-2856. PubMed ID: 31965287
[TBL] [Abstract][Full Text] [Related]
16. Loss of AQP3 protein expression is associated with worse progression-free and cancer-specific survival in patients with muscle-invasive bladder cancer.
Rubenwolf P; Thomas C; Denzinger S; Hartmann A; Burger M; Georgopoulos NT; Otto W
World J Urol; 2015 Dec; 33(12):1959-64. PubMed ID: 25939538
[TBL] [Abstract][Full Text] [Related]
17. Decreased ezrin and paxillin expression in human urothelial bladder tumors correlate with tumor progression.
Athanasopoulou A; Aroukatos P; Nakas D; Repanti M; Papadaki H; Bravou V
Urol Oncol; 2013 Aug; 31(6):836-42. PubMed ID: 21868260
[TBL] [Abstract][Full Text] [Related]
18. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours.
Patard JJ; Rodriguez A; Leray E; Rioux-Leclercq N; Guillé F; Lobel B
Eur Urol; 2002 Jun; 41(6):635-41; discussion 642. PubMed ID: 12074781
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up.
Mathis C; Lascombe I; Monnien F; Bittard H; Kleinclauss F; Bedgedjian I; Fauconnet S; Valmary-Degano S
BMC Cancer; 2018 Dec; 18(1):1239. PubMed ID: 30526555
[TBL] [Abstract][Full Text] [Related]
20. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer.
Fristrup N; Birkenkamp-Demtröder K; Reinert T; Sanchez-Carbayo M; Segersten U; Malmström PU; Palou J; Alvarez-Múgica M; Pan CC; Ulhøi BP; Borre M; Ørntoft TF; Dyrskjøt L
Am J Pathol; 2013 Feb; 182(2):339-49. PubMed ID: 23201130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
